Innoviva (INVA) Competitors $18.63 +0.46 (+2.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.63 0.00 (0.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, MNKD, NVAX, OPK, and GERNShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Innoviva vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies MannKind Novavax OPKO Health Geron Innoviva (NASDAQ:INVA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Do analysts recommend INVA or ALKS? Innoviva presently has a consensus price target of $40.33, suggesting a potential upside of 116.50%. Alkermes has a consensus price target of $41.08, suggesting a potential upside of 54.74%. Given Innoviva's stronger consensus rating and higher possible upside, analysts clearly believe Innoviva is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media favor INVA or ALKS? In the previous week, Alkermes had 29 more articles in the media than Innoviva. MarketBeat recorded 31 mentions for Alkermes and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.25 beat Alkermes' score of 0.92 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 13 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is INVA or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Innoviva's net margin of -16.15%. Alkermes' return on equity of 24.86% beat Innoviva's return on equity.Company Net Margins Return on Equity Return on Assets Innoviva-16.15% 15.77% 8.41% Alkermes 23.15%24.86%17.14% Do insiders and institutionals have more ownership in INVA or ALKS? 99.1% of Innoviva shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 2.3% of Innoviva shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, INVA or ALKS? Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$358.71M3.26$23.39M-$1.01-18.45Alkermes$1.51B2.91$367.07M$2.0812.76 Which has more volatility and risk, INVA or ALKS? Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. SummaryAlkermes beats Innoviva on 12 of the 17 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$239.09B$5.49B$9.54BDividend YieldN/A3.07%4.73%4.09%P/E Ratio-18.4527.1528.8623.83Price / Sales3.264.59371.4866.02Price / Cash5.3012.8435.4557.96Price / Book1.6917.328.275.54Net Income$23.39M$8.49B$3.25B$259.28M7 Day Performance-0.48%-6.28%-3.73%-4.68%1 Month Performance-3.97%-4.73%4.29%4.36%1 Year Performance-2.36%-11.43%25.87%17.89% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva4.183 of 5 stars$18.63+2.5%$40.33+116.5%-3.4%$1.14B$358.71M-18.45100ALKSAlkermes4.7588 of 5 stars$26.66-8.8%$40.92+53.5%-1.2%$4.82B$1.56B12.761,800News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeLGNDLigand Pharmaceuticals4.1926 of 5 stars$141.12+1.5%$147.17+4.3%+27.2%$2.68B$167.13M0.0080Upcoming EarningsAnalyst ForecastHigh Trading VolumeFOLDAmicus Therapeutics4.0015 of 5 stars$6.05+1.5%$16.22+168.1%-38.0%$1.84B$528.29M-67.21480Trending NewsAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.2249 of 5 stars$8.52-1.0%$16.70+96.0%+11.8%$1.80B$450.71M-32.77530News CoverageUpcoming EarningsCLDXCelldex Therapeutics1.2681 of 5 stars$22.06-1.6%$50.11+127.2%-40.9%$1.49B$7.02M-8.17150News CoveragePositive NewsUpcoming EarningsDVAXDynavax Technologies4.1979 of 5 stars$10.94+2.1%$24.00+119.4%-0.5%$1.29B$277.25M-21.04350Upcoming EarningsMNKDMannKind3.2945 of 5 stars$3.82+1.6%$10.14+165.5%-32.4%$1.14B$297.60M38.20400News CoverageUpcoming EarningsAnalyst DowngradeNVAXNovavax4.5827 of 5 stars$7.17+2.4%$17.00+137.1%-47.8%$1.13B$682.16M2.711,990News CoverageUpcoming EarningsGap DownOPKOPKO Health4.0171 of 5 stars$1.40+3.7%$2.75+96.4%-13.5%$1.07B$713.10M-20.002,997News CoverageEarnings ReportGap DownGERNGeron3.0395 of 5 stars$1.23-0.8%$4.61+274.9%-75.5%$789.78M$76.99M-5.8670Upcoming Earnings Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives MannKind Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
